TRDA
Entrada Therapeutics, Inc. (TRDA)
Healthcare • Biotechnology • $7.13 • MCap: 277,618,432
🌐
https://www.entradatx.com • Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Buy Decision Core
Total Score
30
Business Quality
1
Financial Strength
9
Growth Outlook
1
Momentum
2
Price Action
Current
7.13
52W High
16.03
52W Low
5.06
Above 50DMA
7.06 (0.93%)
Above 200DMA
9.67 (-26.27%)
Relative Strength
Relative Strength
-0.02
RS 3M
0.12
RS 6M
-0.43
RS 9M
-0.29
RS 12M
0.39
Fundamentals
Revenue Growth
-0.54%
Earnings Growth
0%
ROE
-0.54%
ROA
-0.29%
Valuation
PE (Fwd)
-2.39
PEG
0
P/B
0.95
Upside
166.48%
Risk
Beta
-0.25
Short %
0.09
Risk Score
7.00
Analyst
Rating
strong_buy
Target
19.00
Beta
-0.25
Analysts
0
Total Score
30
Upside
166.48%
Relative Strength
-0.02
Beta
-0.25
Why Buy?
- PEG Ratio below 1 (attractive valuation)
- Trading below book value
- Trading above 50 DMA
- Analyst upside exceeds 15%
Key Risks
- Revenue growth is negative
- Negative ROE
Score Breakdown
Business
1
1
Financial
9
9
Growth
1
1
Valuation
11
11
Risk
2
2
Momentum
2
2
Technical
52W High: 16.03
52W Low: 5.06
Above 50DMA: 0.93%
Above 200DMA: -26.27%
Valuation
Forward PE: -2.39
PEG: 0
P/B: 0.95
Upside: 166.48%
Risk
Beta: -0.25
Short Float: 0.09%
ROE: -0.54%
ROA: -0.29%